In a joint ecancermedicalscience interview filmed at ASCO 2011 in Chicago, José Baselga and Josep Tabernero describe the early beginnings…
en_news
Recently captured at the 2011 ASCO meeting, Joan Seoane, Director of the Vall d´Hebron Institute of Oncology´s (VHIO) Translational Research Programme talks to ecancermedicalscience
Principle Investigator of VHIO´s Mouse Models of Cancer Therapy Group, Laura Soucek has been awarded this year´s Fero (Fundación de Investigación Oncológica) grant for translational cancer research for her pioneering work using mouse models to counteract tumoral activity triggered by ´the oncogene from Hell´*, Myc.
Hosted by VHIO, ecancermedicalscience Editor, Gordon McVie interviews lead authors of a recent study published in The Lancet
The prize-giving ceremony was held on Thursday 7 April at the head office of the ABC newspaper in Madrid.
Dr. José Baselga, one of Spain’s most prestigious international oncologists and a key figure in the research and treatment of breast cancer, has been distinguished as “Physician of the Year”. This first edition of the ABC Health Awards recognises the outstanding work of medical professionals and institutions in the public and private health sectors.
• The findings of the study, headed by the Breast Cancer Group at the VALL D’HEBRON ONCOLOGY INSTITUTE (VHIO) in Barcelona, present a new treatment option for patients with metastatic breast cancer.
• Eribulin is the first drug in the last 10 years to have an impact on metastatic breast cancer survival rates without having to be combined.
• The drug improves survival rates by 20% and has a very good toxicity profile compared to other chemotherapy drugs.
• The objective of the Phase III clinical trial was to identify the efficacy of a new treatment strategy for metastatic breast cancer.
VHIO researchers have found a gene associated with resistance to HER2+ breast cancer treatment which could point to a new treatment strategy to conquer this disease.
The group led by Dr Joan Seoane, ICREA Research Professor at the VHIO, has carried out the research in glioma, the most common malignant brain tumor. The study published describes how to identify cells with characteristics of stem cells in the interior of the glioma. These cells, known as Glioma initiating cells (GICs), are responsible for initiating the glioma and also for it reappearing after surgical removal.
From September, Dr Baselga combines the scientific management of the Vall d’Hebron Institute of Oncology (VHIO) with his new appointment at the Hematology & Medical Oncology Division at the Cancer Center of the Massachusetts General Hospital at Harvard Medical School in Boston.
Approximately 30% of all breast cancers currently diagnosed have a genetic abnormality
